Ocera Completes Interim Analysis of OCR-002 in Phase 2b STOP-HE Study for the Treatment of Acute Hepatic Encephalopathy
April 01, 2015 at 17:05 PM EDT
Ocera Therapeutics, Inc. (Nasdaq: OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver ...